Multidisciplinary management of brain Metastases

被引:259
作者
Eichler, April F.
Loeffler, Jay S.
机构
[1] Massachusetts Gen Hosp, Pappas Ctr Neurooncol, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA
[3] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA
[4] Harvard Univ, Sch Med, Boston, MA USA
关键词
neoplasm metastasis; brain neoplasms; therapeutics; ionizing radiation; drug therapy;
D O I
10.1634/theoncologist.12-7-884
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Metastatic brain tumors are the most common intracranial neoplasms in adults. The incidence of brain metastases appears to be rising as a result of superior imaging modalities, earlier detection, and more effective treatment of systemic disease. Therapeutic approaches to brain metastases include surgery, whole brain radiotherapy (WBRT), stereotactic radiosurgery (SRS), and chemotherapy. Treatment decisions must take into account clinical prognostic factors in order to maximize survival and neurologic function whilst avoiding unnecessary treatments. The goal of this article is to review important prognostic factors that may guide treatment selection, discuss the roles of surgery, radiation, and chemotherapy in the treatment of patients with brain metastases, and present new directions in brain metastasis therapy under active investigation. In the future, patients will benefit from a multidisciplinary approach focused on the integration of surgical, radiation, and chemotherapeutic options with the goal of prolonging survival, preserving neurologic and neurocognitive function, and maximizing quality of life.
引用
收藏
页码:884 / 898
页数:15
相关论文
共 138 条
[1]   A phase II trial of temozolomide for patients with recurrent or progressive brain metastases [J].
Abrey, LE ;
Olson, JD ;
Raizer, JJ ;
Mack, M ;
Rodavitch, A ;
Boutros, DY ;
Malkin, MG .
JOURNAL OF NEURO-ONCOLOGY, 2001, 53 (03) :259-265
[2]   Temozolomide for the treatment of brain metastases associated with metastatic melanoma: A phase II study [J].
Agarwala, SS ;
Kirkwood, JM ;
Gore, M ;
Dreno, B ;
Thatcher, N ;
Czarnetski, B ;
Atkins, M ;
Buzaid, A ;
Skarlos, D ;
Rankin, EM .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (11) :2101-2107
[3]   Prognostic factors derived from recursive partition analysis (RPA) of radiation therapy oncology group (RTOG) brain metastases trials applied to surgically resected and irradiated brain metastatic cases [J].
Agboola, O ;
Benoit, B ;
Cross, P ;
Da Silva, V ;
Esche, B ;
Lesiuk, H ;
Gonsalves, C .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 42 (01) :155-159
[4]   STEREOTAXIC RADIOSURGERY FOR THE DEFINITIVE, NONINVASIVE TREATMENT OF BRAIN METASTASES [J].
ALEXANDER, E ;
MORIARTY, TM ;
DAVIS, RB ;
WEN, PY ;
FINE, HA ;
BLACK, PM ;
KOOY, HM ;
LOEFFLER, JS .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (01) :34-40
[5]  
AMER MH, 1978, CANCER, V42, P660, DOI 10.1002/1097-0142(197808)42:2<660::AID-CNCR2820420237>3.0.CO
[6]  
2-E
[7]   Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial [J].
Andrews, DW ;
Scott, CB ;
Sperduto, PW ;
Flanders, AE ;
Gaspar, LE ;
Schell, MC ;
Werner-Wasik, M ;
Demas, W ;
Ryu, J ;
Bahary, JP ;
Souhami, L ;
Rotman, M ;
Mehta, MP ;
Curran, WJ .
LANCET, 2004, 363 (9422) :1665-1672
[8]  
[Anonymous], COCHRANE DATABASE SY
[9]   Phase II Randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases [J].
Antonadou, D ;
Paraskevaidis, M ;
Sarris, G ;
Coliarakis, N ;
Economou, I ;
Karageorgis, P ;
Throuvalas, N .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) :3644-3650
[10]  
Antonadou D, 2002, INT J RADIAT ONCOL, V54, P308